I. O. Shmarakov¹, Т. V. Marchyshak¹, V. L. Borschovetska¹,
M. M. Marchenko¹, Z. Yu. Tkachuk²

¹Yuriy Fedkovych Chernivtsi National University, Ukraine;
е-mail: igor.shmarakov@gmail.com;
²Institute of Molecular Biology and Genetics,
National Academy of Sciences of Ukraine, Kyiv;
е-mail: ztkachuk@yahoo.com

Hepatoprotective activity of Nuclex, a pharmaceutical composed of low-molecular yeast RNA, was investigated during acute and chronic thioacetamide-induced hepatotoxicity. It is demonstrated, that Nuclex administration at a dose of 200 mg/kg during acute and chronic liver injury produces hepatoprotective effect, which is associated with decrease in liver parenchyma lesions and in its inflammatory infiltration. Nuclex application attenuates thioacetamide-induced free radical damage of hepatic biopolymers, expressed in the reduction of TBA-reactive products, carbonyl derivatives, and recovery of protein thiol groups and reduced glutathione levels.